Stockscreener 앱 받기
1.93
10.29%
0.18
시간 외 거래:
1.88
-0.05
-2.59%
전일 마감가:
$1.75
열려 있는:
$1.75
하루 거래량:
38,589
Relative Volume:
0.61
시가총액:
$90.92M
수익:
$18.11M
순이익/손실:
$-18.95M
주가수익비율:
-4.4114
EPS:
-0.4375
순현금흐름:
-
1주 성능:
+5.46%
1개월 성능:
+1.58%
6개월 성능:
+8.92%
1년 성능:
-23.11%
1일 변동 폭
$1.75
$1.94
1주일 범위
$1.60
$1.9999
52주 변동 폭
$1.325
$3.5807
에이다진 Stock (ADAG) Company Profile
ADAG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
1.93 | 86.21M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
에이다진 Stock (ADAG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-31 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | 개시 | China Renaissance | Buy |
| 2021-03-08 | 개시 | Goldman | Buy |
| 2021-03-08 | 개시 | Jefferies | Buy |
| 2021-03-08 | 개시 | Morgan Stanley | Overweight |
에이다진 주식(ADAG)의 최신 뉴스
Adagene Receives FDA Approval for Phase 2 Trial of Muzastotug in MSS CRC - AInvest
Adagene Announces Regulatory Update on Clinical Development - GlobeNewswire
Adagene (NASDAQ:ADAG) Trading Up 3.8% – Should You Buy? - Defense World
Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic By Stocktwits - Investing.com India
Adagene advances muzastotug to phase 2 trial after FDA meeting By Investing.com - Investing.com South Africa
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B Meeting with FDA - MarketScreener
Adagene advances muzastotug to phase 2 trial after FDA meeting - Investing.com India
Adagene Advances Clinical Plan for ADG126 in Colorectal Cancer After FDA Meeting - TipRanks
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA - GlobeNewswire
Adagene's Cancer Drug Shows Breakthrough 29% Response Rate, FDA Fast-Tracks Phase 2 Trial - Stock Titan
Adagene Inc. and ConjugateBio Inc. Partner to Develop Novel Antibody Drug Conjugate - MarketScreener
Adagene to provide antibody to ConjugateBio for bispecific ADC development By Investing.com - Investing.com South Africa
Adagene Partners With ConjugateBio to Develop ADC Programs - MarketScreener
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate - GlobeNewswire
Adagene to provide antibody to ConjugateBio for bispecific ADC development - Investing.com
Adagene Enters $30B ADC Market Through Strategic ConjugateBio Partnership for Novel Cancer Therapeutics - Stock Titan
Adagene announces up to $25 million strategic investment from Sanofi - GlobeNewswire
Adagene stock jumps after Sanofi’s $25 million strategic investment By Investing.com - Investing.com India
Adagene (NASDAQ:ADAG) Trading 0.3% Higher – Here’s Why - Defense World
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Is McKesson (MCK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - Bernama
Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World
Adagene to Present at Jefferies Global Healthcare Conference 2025 - The Manila Times
Adagene Inc. to Participate in Jefferies Global Healthcare Conference 2025 with Fireside Chat and Investor Meetings - Nasdaq
Exclusive: Adagene Leadership Reveals Latest Antibody Therapeutic Strategy at Major Jefferies Conference - Stock Titan
Adagene (NASDAQ:ADAG) Trading Down 2.1% – Here’s Why - Defense World
Adagene Reports Promising ADG126 Study Results at ASCO - TipRanks
Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire
New Clinical Data: Adagene's ADG126 Achieves Breakthrough 29% Response Rate in Hard-to-Treat Colorectal Cancer - Stock Titan
ADAGAdagene Inc. Latest Stock News & Market Updates - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor - GlobeNewswire
Biotech Pioneer Behind $25B Alnylam Success Story Takes Strategic Role at Adagene's Cancer Drug Mission - Stock Titan
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Adagene Inc. Announces Poster Presentation on ADG126 at ASCO 2025 Conference - Nasdaq
Adagene Announces Upcoming Poster Presentation on Masked - GlobeNewswire
Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum - The Manila Times
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum - GlobeNewswire
Adagene Reveals New Oncology Strategy: CEO Set for Major Investor Presentation - Stock Titan
FY2025 Earnings Estimate for Adagene Issued By HC Wainwright - Defense World
Adagene (NASDAQ:ADAG) Earns “Buy” Rating from HC Wainwright - Defense World
Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa
Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com
Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World
Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan
Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire
Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq
에이다진 (ADAG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):